PAX3 and metastatic neoplasm: In metastatic disease, patients with PAX7::FOXO1 aRMS were significantly younger compared to PAX3::FOXO1 positive group (68% vs. 33% of patients ≤10 years of age), all other factors were similarly distributed (Table S5).